Status:
COMPLETED
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Lead Sponsor:
Eisai Inc.
Conditions:
Gastroesophageal Reflux Disease (GERD)
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux di...
Detailed Description
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabepr...
Eligibility Criteria
Inclusion
- KEY INCLUSION CRITERIA:
- Male or female, ages 18 to 75 years.
- History of gastroesophageal reflux disease (GERD) symptoms for at least 3 months immediately before screening.
- Heartburn for at least 2 days a week for at least 1 month before screening.
- Esophageal erosions of Los Angeles (LA) Grades A or B based on EGD taken within 14 days prior to enrollment.
- Subjects who are H. pylori negative based on a screening test.
- Females should be either of non-childbearing potential or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of contraception.
- Subjects must be able to read, write, and understand the language of the symptom diary.
- KEY EXCLUSION CRITERIA:
- Current or a history of esophageal motility disorders.
- Current or a history of Barrett's esophagus. Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).
- Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.
- Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.
- Inflammatory bowel disease.
- Unstable diabetes mellitus.
- History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.
- Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral steroids (\>=20 mg/day prednisone or equivalent), or aspirin (\> 325 mg/day).
Exclusion
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
1397 Patients enrolled
Trial Details
Trial ID
NCT00658632
Start Date
February 1 2008
End Date
September 1 2009
Last Update
May 4 2016
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville, Alabama, United States, 35801
2
Tucson, Arizona, United States, 85712
3
Tucson, Arizona, United States, 85741
4
Little Rock, Arkansas, United States, 72205